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BACKGROUNDAIM: In growth disorders, ensuring long-term growth hormone
therapy (GHT) remains a challenge that might compromise the clinical outcome.
Consequently, strategies aiming at alleviating the burden of daily injection might
improve the treatment benefit. The study reported here was performed to assess the
ease of use of Norditropin NordiFlex((R)) (Novo Nordisk, Princeton, NJ, USA)
compared with that of the devices previously used in children treated with GHT with
recombinant somatropin. METHODS: This Phase IV prospective, multicenter, open-
label study was conducted in France. All patients received Norditropin NordiFlex for
6 weeks. Oral questionnaires were administered by the physician to the patients
and/or the parents at inclusion and at the final visit. RESULTS: This study included
103 patients aged between 6 and 17 years. The patients assessed Norditropin
NordiFlex as significantly easier to use than their previous device (median value =
7.5, P < 0.001). Almost three-quarters of patients (64.4%) preferred Norditropin
NordiFlex to their previous device. Among physicians and nurses, 73% assessed
Norditropin NordiFlex training as "very easy" and 26% as "easy." Norditropin
NordiFlex improved patient autonomy, with 41% of patients able to self-inject the
treatment. CONCLUSION: This study has shown that Norditropin NordiFlex is
reliable, safe, and easy to use and most study patients preferred it to their previous
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